CatalYm GmbH : Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.